April 17, 2025
TOPLINE: Treatment with an aromatase inhibitor, either alone or in combination with growth hormone (GH), slowed bone advancement and enhanced adult height in mid-pubertal boys with […]
April 16, 2025
TOPLINE: Financial hardship, reduced physical activity, increased leisure screen time, depressive and anxiety symptoms, and emotional eating were linked to an increase in body mass index […]
April 15, 2025
Continuous glucose monitoring (CGM) devices may overestimate blood glucose levels in healthy adults, potentially leading to unnecessary dietary changes and confusion among users, according to a […]
April 15, 2025
Medically supervised resistance training and adequate protein intake may help minimize the loss of lean body mass in people taking glucagon-like peptide 1 receptor agonists (GLP-1 […]
April 14, 2025
The U.S. Food and Drug Administration (FDA) and Novo Nordisk are warning people not to use counterfeit semaglutide 1.0 mg (Ozempic injection) found in the US […]
April 11, 2025
Malnutrition-related diabetes, distinct from both type 1 and type 2, has now been officially recognized and named “type 5 diabetes.” The vote to endorse the category […]
April 11, 2025
The adjunctive use of glucagon-like peptide 1 receptor agonists (GLP-1 RA) as an addition to insulin is increasingly viewed as a method for addressing the rising […]
April 11, 2025
At least two recent studies have found bariatric surgery more cost-effective, long term, than the pricey glucagon-like peptide 1 (GLP-1) receptor agonist obesity medications. Another recent […]
April 10, 2025
The Dexcom G7 continuous glucose monitor (CGM) will now last 15 days, up from the previous 10-day version. The US Food and Drug Administration’s clearance of […]